Targeted therapy and their ocular complications

Clinical Ophthalmic Oncology: Basic Principles and Diagnostic Techniques, Second Edition

Volumn , Issue , 2014, Pages 123-132

  Jusufbegovic, Denis ^a   Pierre, L ^b   Singh, Arun D ^b  

^a University of Louisville School of Medicine   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956758035     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-40489-4_13     Document Type: Chapter

References (51)

1. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012; 6(2): 155-76.
2. Myskowski PL, Halpern AC. Skin reactions to the new biologic anticancer drugs. Curr Opin Support Palliat Care. 2009; 3(4): 294-9.
3. Hedhli N, Russell KS. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev. 2011; 7(4): 221-33.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-7.
5. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000; 289(5486): 1938-42.
6. Fletcher JA. Role of KIT and platelet-derived growth factor receptors as oncoproteins. Semin Oncol. 2004; 31(2 Suppl 6): 4-11. Review.
7. Heuchel R, Berg A, Tallquist M, et al. Platelet-derived growth factor B receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3kinase signaling. Proc Natl Acad Sci U S A. 1999; 96: 11410-5.
8. Demetri G, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-80.
9. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003; 19: 371-5.
10. Esmaeli B, Diba R, Ahmadi MA, Saadati HG, Faustina MM, Shepler TR, Talpaz M, Fraunfelder R, Rios MB, Kantarjian H. Periorbital Oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec). Eye (Lond). 2004; 18(7): 760-2.
11. Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, Alimena G. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res. 2008; 32(7): 1022.
12. Kitzmann AS, Baratz KH, Mohney BG, Pulido JS, Cameron JD, Lee ES, Leof EB. Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits. Eye (Lond). 2008; 22(5): 712-4.
13. Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). Anticancer Res. 2012; 32(4): 1375-7.
14. Masood I, Negi A, Dua HS. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg. 2005; 31: 2427-8.
15. Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol. 2008; 52(4): 331-3.
16. Babu KG, Attili VSS, Bapsy PP, Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol. 2007; 27: 43-4.
17. Bajel A, Bassili S, Seymour JF. Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib. Leuk Res. 2008; 32(11): 1789-90.
18. Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer. 2013; 21(4): 1167-74.
19. Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg. 2007; 23: 65-6.
20. Zhang G, Basti S, Jampol LM. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea. 2007; 26(7): 858-60.
21. Saint-Jean A, Sainz de la Maza M, Morral M, Torras J, Quintana R, Molina JJ, Molina-Prat N. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012; 119(9): 1798-802.
22. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med. 2008; 59: 429-42.
23. Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond). 2005; 19(7): 729-38.
24. Holubec L, Liska V, Matejka VM, Fiala O, Dreslerova J, Mrazkova P, Treska V, Finek J. The role of cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res. 2012; 32(9): 4007-11.
25. Van Cutsem E, Siena S, Humblet Y, et al. An openlabel, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008; 19: 92-8.
26. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719-26.
27. Guler M, Yilmaz T, Ozercan I, Elkiran T. The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol. 2009; 147: 703-8.
28. Burris 3rd HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011; 29(4): 398-405.
29. Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D. Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncol. 2011; 50(3): 477-8.
30. Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther. 2012; 12(5): 567-80.
31. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med. 2011; 364(20): 1897-908.
32. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012; 130(8): 972-9.
33. Sherman JH, Aregawi DG, Lai A, Fathallah-Shaykh HM, Bierman PJ, Linsky K, Larner JM, Newman SA, Schiff D. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology. 2009; 73(22): 1924-6.
34. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006; 354: 980-2.
35. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006; 354: 980-2.
36. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007; 25: 3559.
37. Khan KH, Fenton A, Murtagh E, McAleer JJ, Clayton A. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori. 2012; 98(5): 139e-42.
38. Yoong J, Chong G, Hamilton K. Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma. Med Oncol. 2011; 28 Suppl 1: S395-7.
39. Wegner A, Khoramnia R. Neurosensory retinal detachment due to sunitinib treatment. Eye (Lond). 2011; 25(11): 1517-8.
40. Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012; 8(5): 623-33.
41. Dogan SS, Esmaeli B. Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. Hematol Oncol Clin North Am. 2009; 23(1): 109-14, ix.
42. Keenan JD, Fram NR, McLeod SD, Strauss EC, Margolis TP. Perifosine-related rapidly progressive corneal ring infiltrate. Cornea. 2010; 29(5): 583-5.
43. Curran MP. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs. 2012; 72(1): 99-107.
44. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1): 103-19.
45. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris 3rd HA, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 doseescalation trial. Lancet Oncol. 2012; 13(8): 773-81.
46. Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, Eberhardt WE. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res. 2012; 18(17): 4794-805.
47. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8): 707-14.
48. Jordan EJ, Kelly CM. Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012; 13(17): 2533-43.
49. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004; 27: 478-9.
50. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30(21): 2691-7.
51. Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg. 2011; 27(4): e87-8.